Form 4: Hepion Pharmaceuticals Exec Acquires Shares

Gary S. Stetz, Interim CEO and Director of Hepion Pharmaceuticals, acquired 1,250,000 shares of common stock.

Summary

• Gary S. Stetz, who holds the positions of Interim CEO and Director at Hepion Pharmaceuticals, Inc., acquired 1,250,000 shares of the company's common stock.
• The transaction occurred on April 21, 2026, with the shares acquired at a price of $0.04 per share.
• Following this transaction, Mr. Stetz beneficially owns 1,250,000 shares, held indirectly through the Stetz Belgiovine CPA 401K F/B/O Gary S. Stetz.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development due to the insider acquisition, which can indicate confidence, but the filing itself is purely transactional and lacks broader company performance data.

Positives

• Insider buying can signal confidence in the company's future prospects.
• The acquisition of a significant number of shares by a key executive may be interpreted positively by the market.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that insider transactions, particularly acquisitions by senior management, are closely watched as they can provide insights into management's perception of the company's valuation and future performance within the pharmaceutical sector.

Stakeholder Impact

• Shareholders may view this acquisition positively, interpreting it as a sign of management's confidence in the company's stock value.

Key Dates

Keywords

Hepion Pharmaceuticals, HEPA, Form 4, Insider Trading, Stock Acquisition, Gary S. Stetz, Interim CEO, Director